Compare AdaptHealth Corp (AHCO) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs Nomura Holdings Inc — how do they compare? AdaptHealth Corp trades at $5.72 (market cap $753.09M), while Nomura Holdings Inc trades at $9.82 (market cap $28.46B). The key difference: Nomura Holdings Inc is far larger — about 37.8× AdaptHealth Corp's market cap, and Nomura Holdings Inc pays a 3.31% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | NMR | |
|---|---|---|
Market Cap | $753.09M | $28.46B |
Sector | Health | Financials |
52-Week High | $13.38 | $10.04 |
52-Week Low | $5.22 | $6.73 |
Enterprise Value | $2.77B | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.77, up 10.54% today but remains under significant pressure following recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal revenue growth but negative profitability margins. Recent news highlights multiple securities fraud investigations and a strategic shift through the sale of its diabetes unit to focus on sleep and respiratory care.
Despite 75% analyst buy ratings and an $11 consensus price target suggesting substantial upside, immediate risks are elevated. The company faces execution challenges with fixed-price contracts, ongoing legal scrutiny, and consecutive earnings misses. Investors must weigh the potential recovery against substantial operational and legal headwinds.
Nomura Holdings (NMR) trades at $9.925, up 1.07% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst consensus leans toward Hold, with 66.67% of coverage recommending Hold and 33.33% Buy.
The outlook for NMR is supported by robust profitability and valuation metrics like a P/E of 11.59, suggesting potential undervaluation. However, risks include inconsistent cash flow from operations, rising debt-to-asset ratios, and macroeconomic sensitivity. Investors should weigh solid fundamentals against cash flow volatility and debt trends for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
